Q2 FY27 profit rises 57% as revenue grows 30%

Compliance View source PDF Explain this filing

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹523.95

prior close

₹527.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 171sector+0.5%-1.6% vs sector

On the reaction day the stock moved 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-2.8

15m

-1.3

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1pendingpending+0.5-1.6

Next day

-4.7pendingpending+0.4-5.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SMS Pharmaceuticals reported strong unaudited Q2 and H1 FY27 results. Q2 revenue rose 30% year on year to ₹316.08 crore, profit after tax increased 57% to ₹39.57 crore, and EBITDA margin reached 21%. H1 revenue rose 19% to ₹523.05 crore and net profit rose 36% to ₹59.76 crore. Management expects FY27 revenue growth and EBITDA margins to exceed earlier guidance. The ₹280 crore expansion plan remains on track, with ₹160 crore spent.

Likely market impact

Positive: stronger earnings, higher margins and expectations of exceeding FY27 guidance may support the stock. New capacity ramp-up remains a risk.